• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CESAR and Saladax collaborate on a study of optimized 5-FU dosing in colorectal cancer patients

CESAR and Saladax collaborate on a study of optimized 5-FU dosing in colorectal cancer patients

February 14, 2012
CenterWatch Staff

Saladax Biomedical and the Central European Society for Anticancer Drug Research (CESAR) will be collaborating in a single-arm study of metastatic colorectal cancer patients treated with the chemotherapy drug 5-fluorouracil (5-FU).

CESAR will sponsor the Saladax-supported study designed to determine whether target blood levels of 5-FU can be maintained throughout the course of treatment by optimizing the dose administered to individual patients at each infusion. Doses in the study will be optimized based on actual 5-FU blood levels, which will be measured using Saladax's My5-FU automated immunoassay technology.

The goals of the study are to achieve a stable target blood level of 5-FU and to determine whether this dose optimization is able to reduce 5-FU-related toxicities.

“We expect that the 5-FU clinical trial we are undertaking will add to the growing body of evidence that pharmacokinetic optimization of 5-FU dosing has the potential to markedly improve patient quality of life through a reduction of grade 3/4 mucositis and diarrhea, which can result in hospitalization and premature treatment termination,” explained Dr. Martin Wilhelm of CESAR, chair of the study.

The four-center study is planned to enroll 80 metastatic colorectal cancer patients and is expected to be completed within one year.  Individual patients will remain on study until a total of six doses of 5-FU treatment have been administered and the end-of-treatment visit has been performed.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing